


# IMMUNOGEN

ImmunoGen, Inc.  
Investor Relations Department  
830 Winter Street  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## NASDAQ: IMGN

Last Trade:	6.00
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	0.03  (+0.503%)
Day Range	5.89 - 6.36
52-Week Range	1.51 - 8.84
Volume	3,543,677

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Oct 16, 2017

[ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active](#)

Oct 11, 2017

[ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares](#)

Oct 5, 2017

[ImmunoGen Announces Pricing of Public Offering of Common Stock](#)

Oct 4, 2017

[ImmunoGen Announces Proposed Public Offering of Common Stock](#)

Sep 5, 2017

[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

Aug 25, 2016

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)